21 results
Thumbnail

D1.74 - Molecular IgE sensitization profiling in a patient with Asteraceae weed pollen allergy and anaphylaxis to honey

Thumbnail

D1.75 - Anaphylaxis during Picc Line replacement

Thumbnail

D1.76 - The Hot Chocolate Drink Dilemma

Thumbnail

D1.77 - Perioperative Hypersensitivity Outcomes: A retrospective review of 112 patients seen between 2019 and 2024 at two allergy centres

Thumbnail

D1.78 - Analytical Verification of Omega-5 gliadin (Tri a 19) Allergen Assay on the IMMULITE 2000 XPi System*

Thumbnail

D1.79 - Cardiovascular symptoms during anaphylaxis: An analysis from the European Anaphylaxis Registry

Thumbnail

D1.82 - Diagnostic challenges in amoxicillin-clavulanate anaphylaxis: an inconclusive in vitro study – Case Report

Thumbnail

D1.83 - Asthma and multi-food allergy were risk factors for Oral Food Challenge failure

Thumbnail

D1.84 - IgE-mediated allergy to chlorhexidine: case report

Thumbnail

D1.85 - Basophil activation test in β-Lactam Anaphylaxis: A Case Series from a Tertiary Hospital

Thumbnail

D1.86 - Hypersensitivity Reaction to Lugol’s Solution: A Case Report

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center